Current situation of chronic myeloid leukemia in Costa Rica
DOI:
https://doi.org/10.51481/amc.v60i1.988Abstract
Background and aim: Chronic myeloid leukemia is a paradigm of reversion of neoplasia with a specific treatment based on tyrosine kinase inhibitors. Although the epidemiological situation has been studied in first world countries, studies in Latin American countries are scarce. In order to update the real situation of the chronic myeloid leukemia in our Central American region, this study aims to describe the epidemiology of chronic myeloid leukemia in Costa Rica.
Methods: 133 patients with the disease were evaluated through hematological and molecular monitoring. The response of these cases to treatment was analyzed by the following variables: haematological response, molecular response and overall survival, event-free, progression, as well as the prevalence of mutations that confer resistance to treatment.
Results: The complete haematological response was 97.7% and the molecular response greater than 12 months was 43.4%. The follow-up recommended by the European LeukemiaNet guideline was reached in only 68.4% of the patients in the first year, decreasing to 57.7% later on. A total of 92 patients achieved a higher molecular response at some point, of which 87.0% retained a response. The 3-year event-free survival was 65.7%, progression free of 92.2% and overall of 89.2%. The most frequent mutation found in the ABL gene was T315I.
Conclusion: The treatment of chronic myeloid leukemia in Costa Rica presents an efficacy comparable to that reported in other countries, with a lower molecular response than expected due to difficulties in accessing medication and monitoring the disease.
Downloads
References
Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447-1459. doi:
1016/S0140-6736(13)62120-0.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-884. doi: 10.1182/ blood-2013-05-501569.
Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia. 2003;17:2318-2357. doi: 10.1038/sj.leu.2403135.
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCRABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208-1215. doi: 10.1182/blood-2010-12-326405.
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphatebinding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475. doi: 10.1182/blood. V99.9.3472.
Amaru R, Torres G, Peñaloza R, Miguez H, Velarde J, Huarachi N, et al. Epidemiología de las leucemias en Bolivia: 1473 casos. Enero 1999 a mayo de 2012. Rev Med La Paz. 2012;18:9-19.
Mendizabal AM, Garcia-González P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle-income countries. Cancer Epidemiol. 2013;37:247-254. doi: 10.1016/j.canep.2013.01.002.
Pavlovsky C, Fernández I, Pavlovsky MA, Sackmann F, Remaggi G, Pavlovsly S. Diez años de seguimiento y monitoreo de 87 pacientes con leucemia mieloide crónica tratados con inhibidores de cinasa de tirosina: experiencia en FUNDALEU, Buenos Aires, Argentina. Rev Hematol Mex. 2011;12:11-16.
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. doi: 10.1056/NEJMoa030513.
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. doi: 10.1056/NEJMoa022457.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. doi: 10.1056/ NEJMoa062867.
Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117:5591-559. doi: 10.1182/blood-2010-12-324228.
Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, et al. Current patient management of chronic myeloid leukemia in Latin America: A study by the Latin American Leukemia Net (LALNET). Cancer. 2010;116, 4991-5000. https://doi.org/10.1002/cncr.25273
Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018-1029. doi: 10.1016/S14702045(07)70342-X.
Cervantes F, López-Garrido P, Montero M-I, Jonte F, Martínez J, HernándezBoluda J-C, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica. 2010;95:1317-1324. doi.
3324/haematol.2009.021154.
Downloads
Published
Versions
- 2018-01-04 (2)
- 2018-01-04 (1)
Issue
Section
License
Copyright (c) 2018 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
